EMA accepts BMS’ Opdivo application in oesophageal cancer
Phase III trial showed significant survival benefit over chemotherapy alone
Read More
Tag: Yervoy
MHRA approves Opdivo plus Yervoy for unresectable malignant pleural mesothelioma
First treatment to be approved for UK MPM patients for more than 15 years
Read More
EC green light for Opdivo plus Yervoy in metastatic colorectal cancer
Immunotherapy regimen approved to treat metastatic colorectal cancer after prior chemotherapy
Read More
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients
Immunotherapy combo approved for the treatment of advanced bowel cancer patients with rare MSI-H/dMMR mutations
Read More
Opdivo combos show OS benefit in advanced oesophageal cancer
Opdivo plus chemotherapy or Yervoy demonstrated overall survival benefit in PD-L1-positive and all-randomised populations
Read More
Opdivo, Yervoy combination approved to treat malignant pleural mesothelioma
Combination immunotherapy treatment approved in the EU for first-line treatment of adults with unresectable MPM
Read More
Opdivo plus Yervoy moves closer to EU approval for dMMR/MSI-H colorectal cancer
CHMP recommended EU approval for combination treatment in its May decisions
Read More
BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients
At six and a half years 49% of patients treated with combination therapy remained alive
Read More
NICE ‘no’ for Opdivo/Yervoy lung cancer combo
The combination is not considered to be a cost-effective use of NHS resources in this setting
Read More
Opdivo plus Yervoy combo approved in EU for first-line lung cancer
New approval marks third indication for an Opdivo plus Yervoy-based regimen in the EU
Read More
BMS’ Opdivo plus Yervoy misses the mark in high-risk melanoma
Combination treatment did not achieve statistical significance in all-comer population
Read More
Opdivo/Yervoy improves survival in pleural mesothelioma
Combination therapy showed benefit in hard-to-treat cancer type
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
